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Abstract. 
BACKGROUND: The role of serum biomarkers in the surveillance of hepatocellular carcinoma 
(HCC) is controversial. 
OBJECTIVE: We assessed the diagnostic performances of alpha-fetoprotein (AFP) and protein-
induced by vitamin-K absence/antagonist-II (PIVKA-II) in 388 cirrhotic patients with chronic liver 
disease (CLD). 
METHODS: Biomarkers were quantified by automated chemiluminescent-enzyme-immunoassays 
(Fujirebio, Tokyo, Japan) at HCC diagnosis in 258 patients (204 males; median age 66.9 years) and 
in 130 cirrhotics without HCC (104 males; median-age 60.6 years). CLD etiology in HCC/non-
HCC was CHB in 48/35, CHC in 126/56 and Non-Viral in 84/39. 
RESULTS: Overall AUROC values for AFP and PIVKA-II were 0.698 (95%CI = 0.642–0.753, P 
<0.001) and 0.780 (95%CI = 0.730–0.831,P <0.001). AFP/PIVKA-II AUROC (95%CI) were: 
0.822 (0.728–0.915)/0.833 (0.739–0.926) in CHB, 0.648 (0.560–0.736)/0.732 (0.650–0.814) in 
CHC; 0.640 (0.540–0.740)/0.806 (0.722–0.889) in Non-Viral-CLD. AFP/PIVKA-II diagnostic 
accuracy was 40.5–59.8%/62.7–73.5% and combining both markers 78.2% for CHB, 77% for Non-
Viral-CLD and 75% for CHC. AFP correlated with ALT in HCC patients with CHC (r = 0.463/P 
<0.001) and Non-Viral CLD (r = 0.359/P = 0.047), but not in CHB (treated with antivirals). 
PIVKA-II correlated with tumour size independently of CLD-etiology (P < 0.001) and AFP in CHB 
patients only (P = 0.007). 
CONCLUSION: The diagnostic performance of AFP and PIVKA-II is significantly influenced by 
the etiology and activity of CLD; their combination provides a better diagnostic accuracy. 
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Introduction 
Hepatocellular carcinoma (HCC) is the fifth most common cancer in men and the seventh in women 
worldwide [1]. Chronic liver disease (CLD) induced by chronic infection with major hepatitis 
viruses (hepatitis B, C and D viruses) and/or steatohepatitis are the main causes of HCC that 
associates with cirrhosis in about 90% of cases [2]. Age- and sex-specific HCC rates  vary in 
different geographic regions in relation to differences in the prevalence of hepatitis virus infections 
and other co-factors of CLD. The highest incidence of HCC occurs in sub-Saharan Africa and 
Eastern Asia with about 20 per 100,000 individuals and the lowest in North America, South 
America, Northern Europe, and Oceania (5.0 per 100,000 individuals). Italy and other Southern 
European countries such as Spain and Greece show mid-incidence levels (12.0 per 100,000 
individuals) [1–3]. Given an incidence rate higher than 1.5% year in at-risk population, such as 
cirrhotic patients,surveillance programs have a positive cost-benefit ratio because diagnosis in early 
stage may significantly improve the management of HCC [4]. Ultrasonography (US) is the imaging 
technique used for surveillance because of its effectiveness in HCC detection despite the limitations 
due to the operators’ expertise [5]. 
In the past alpha-fetoprotein (AFP) was combined to US, but at present it is not any more 
recommended by European and American guidelines [4,6] because of a suboptimal diagnostic 
performance of serum biomarkers of HCC in clinical practice [7–9]. AFP shows highly variable 
rates of both sensitivity (ranging from 50–70%) and specificity (45–85%) because its serum levels 
are influenced by liver regeneration following necrosis and inflammation [10,11]. On the other hand 
the diagnostic performance of protein induced by vitamin-K absence/antagonist-II [PIVKA-II, also 
known as des-gamma-carboxyprothrombin (DCP)], a marker of oncogenic mechanisms associated 
with neovascularization [12–14], was evaluated almost exclusively in patients with hepatitis C virus 
(HCV) infection [15]. At present the combination of AFP and PIVKA-II biomarkers for HCC 
diagnosis is proposed only in Japan [16] where most of HCC cases occur in HCV infected patients 
[17]. Therefore, several factors depending on liver disease etiology, disease activity and liver 
regeneration could be responsible for the variability of the results because of the heterogeneity of 
the studied populations. The importance of such confounding factors could become even more 
relevant nowadays after the introduction of highly effective antiviral treatment for chronic hepatitis 
B and C patients [18–21].We studied the impact of etiology and activity of chronic liver disease in 
the diagnostic performance of AFP and PIVKA-II in cirrhotic patients with and without HCC. 
 
2. Patients and methods 
2.1. Patients 
We studied retrospectively 388 consecutive patients with liver cirrhosis, enrolled in three Italian 
Hepatology centres [163 (42.0%) in Padua, 180 (46.4%) in Pisa, 45 (11.6%) in Turin]: 1) 258 
cirrhotic patients with HCC (diagnosis performed from 2010 to 2015), for whom a serum sample at 
the time of diagnosis was available; 2) 130 cirrhotic patients on ultrasound (US) surveillance for at 
least 12 months, without evidence of HCC and with a serum sample available at the beginning of 
their follow-up. Liver cirrhosis was diagnosed by clinical, biochemical and imaging data (presence 
of US signs and transient elastography > 13 kPa) or liver biopsy: all the patients underwent every 6 
month US surveillance during a median follow-up of 25.2 months (range 12.0–67.2). HCC 
diagnosis and staging were performed according to EASL guide-lines and BCLC classification 
[6,22]. The underlying CLD was classified in three different groups by etiology: i) Chronic 
Hepatitis B (CHB), HBsAg positive;  
ii) Chronic Hepatitis C (CHC), anti-HCV/HCV-RNA positive; iii) Non-Viral CLD, HBsAg and 
anti-HCV negative. The study was approved by the local Ethical Committee and fulfilled the 
guidelines of the Declaration of Helsinki (7th revision, 2013). All patients gave their written 
informed consent. 
 
2.2. Serological assays  
Quantitative measurements of AFP and PIVKA-II were performed on sera stored at -20°C since 
they were obtained at the time of diagnosis in 258 HCC patients or at a single point evaluation in 
130 cirrhotic patients without HCC during their surveillancefollow-up. AFP and PIVKA-II serum 
levels were measured using fully automated chemo-luminescent enzyme immunoassays (CLEIA) 
on Lumipulse G1200 (Fujirebio Inc, Tokyo, Japan). The analytical sensitivity was 0.8 ng/mL for 
AFP and 1.37 mAU/mL for PIVKA-II. The dynamic range of quantification was 0.8–22,451 ng/mL 
for AFP and 1.37–75,000 mAU/mL for PIVKA-II and their upper limit of normality were 7.4 
ng/mL and 48 mAU/mL respectively. Samples with results exceeding the dynamic range were 
retested following appropriate dilutions. Tests were performed in a single run at a single reference 
laboratory according to the manufacturer’s instruction. 
 
2.3. Statistical analysis 
Quantitative variables were expressed as median and ranges. Differences between the groups of 
etiology were analysed using Mann-Whitney or Kruskal-Wallis tests and corrected Chi-square test 
for continuous and categorical variables respectively. Multivariate analysis was performed by 
logistic regression. The correlations between biomarkers and with ALT levels and tumour size (in 
HCC patients) were performed with  nonparametric Spearman rank test. Receiver operating 
characteristic (ROC) curves were plotted for each assay in the overall population and according to 
the etiology of CLD. Areas under ROC curves (AUROC) were evaluated and compared by using 
MedCalc for  Windows, version 15.0 (MedCalc Software, Ostend, Belgium). Diagnostic 
performances of AFP, PIVKAII and their combination were determined by calculating sensitivity 
(Se), specificity (Sp), positive predictive value (PPV), negative predictive value (NPV) and 
diagnostic accuracy (DA), using several fixed cut-off values, both overall and according to the 
etiology of CLD. The thresholds used as cut-offs were arbitrarily chosen in accordance to previous 
studies [23–26]: 10–20–100 and 400 ng/mL for AFP and 40–48–70 and 150 mAU/mL for PIVKA-
II. P values < 0.05 were considered as significant. All statistical analyses were performed by SPSS 
(version 20.0, SPSS Inc., Chicago, 
129 IL, USA). 
 3. Results 
Demographic, laboratory and clinical data of the 388 cirrhotic patients (258 with HCC and 130 
without  HCC) are reported in Table 1. The etiology of CLD was CHB, CHC and Non-Viral CLD 
in 83 (21.4%), 182 (46.9%) and 123 (31.7%) patients, respectively, Liver disease was alcohol-
induced in 63 of the 123 (51.2%) patients with Non-Viral CLD, 56 (45.5%) of them had non-
alcoholic steatohepatitis (NASH) and 4 (3.3%) autoimmune hepatitis. HCC was present in 48 of 83 
CHB (57.8%), 126 of 182 CHC (69.2%) and 84 of 123 Non-Viral CLD (68.3%) patients. Fifty-
seven of 83 (68.7%) CHB patients (27 with and 30 without HCC) were on nucleos(t)ide analogues 
(NUCs) treatment. Median age was higher in HCC patients than in cirrhotics (66.9 vs 60.6 years, P 
< 0.001). ALT levels were not significantly different in patients with or without HCC [41 (9–480) 
vs 36 (9–312) U/L, P = 0.299]. Overall, CHC patients showed higher ALT values than CHB and 
Non-Viral CLD [75 (10–480) vs 
150 26.5 (9–168) and 29 (9–229) U/L, P < 0.001)]. Median ALT levels of patients with or without 
HCC were comparable in CHC [78 (10–310) vs 72 (15–480) U/L, P = 0.343] and Non-Viral CLD 
[30 (12–229) vs 28 (9–132) U/L, P = 0.627] groups. On the contrary, in CHB patients, median ALT 
levels were significantly higher in patients with HCC (27 out of 48 on NUCs) than in those without 
HCC (30 out of 35 on NUCs) [29.0 (12–168) vs 22.5 (9–153) U/L, P = 0.032]. In 258 HCC patients 
the BCLC staging at diagnosis was: 0 in 56 (21.7%), A in 141 (54.7%), B in 37 (14.3%) and C in 
24 (9.3%); none of the patients was diagnosed on stage D. According to etiology of CLD the HCC 
staging in CHB, CHC and Non-Viral patients was: 0 in 13 (27.1%), 37 (29.3%) and 6 (7.1%), A in 
23 (47.9%), 77  
(61.1%) and 41 (48.8%), B in 5 (10.4%), 5 (4.0%) and 27 (32.1%), C in 7 (14.6%), 7 (5.6%) and 10 
(12.0%) (P <0.001) respectively. 
 
3.1. AFP and PIVKA-II serum levels according to etiology of CLD 
Median serum levels of AFP [8.6 ng/mL (1.1–1,366,736)] and PIVKA-II [68 mAU/mL (5–
181,690)]  
were significantly higher in patients with HCC than in those without HCC (P < 0.001 for both 
groups):  
11.4 ng/mL (1.1–1,366,736) and 150.5 mAU/mL (7–181,690) versus 5.2 ng/mL (1.4–255.2) and 34 
mAU/mL (5–68,989) respectively. At multivariate logistic regression analysis older age (OR 1.047,  
95% CI 1.019–1.075, P = 0.001), and higher AFP and PIVKA-II levels (OR 2.656, 95% CI 1.612–
4.376, P < 0.001, and OR 3.308 95% CI 1.994–5.487, P < 0.001, respectively) were independently 
associated with HCC (Table 1). The difference of median AFP and PIVKA-II levels between 
patients with and without HCC remained statistically significant after stratification by CLD etiology 
(Table 2 and Fig. 1). AFP median levels were similar in CHB and Non-Viral HCC patients [6.5 
ng/mL (1.2–1,366,736) and 7.5 ng/mL (1.1–10,525), respectively, P = 0.334], but higher in CHC 
[20.3 ng/mL (2.1–81,123.4), P = 0.007 vs CHB and P < 0.001 vs Non-Viral]. In cirrhotics without 
HCC, AFP levels significantly differed among CHB [2.8 ng/mL (1.4–14.0)], CHC [11.2 ng/mL 
(3.0–255.2)] and Non-Viral [4.2 ng/mL (1.6–12.9)] groups (CHC vs CHB, P < 0.001; CHC vs Non-
Viral, P < 0.001; CHB vs Non-Viral, P = 0.004). PIVKA-II median levels in HCC patients were 
similar in CHB [85 mAU/mL (21–73,068)] and CHC groups [137.5 mAU/mL (7–96,463)] (P = 
0.636), but significantly higher in the Non-Viral CLD group [266 mAU/mL (8–181,690)] (P = 
0.042 vs CHB and P = 0.047 vs CHC). In patients without HCC PIVKA-II levels were comparable 
in all CLD groups: 32 mAU/mL (5–68,989), 35 mAU/mL (10–22,515) and 35 mAU/mL (8–1,224) 
in CHB, CHC, and Non-Viral CLD, respectively (CHC vs CHB, P = 0.289; CHC vs Non-Viral, P = 
0.550; CHB vs Non-Viral CLD, P = 0.142). 
 
3.2. AFP and PIVKA-II correlations and diagnostic performance 
AFP and PIVKA-II levels correlated with each other significantly, but the ⇢ was low both overall 
(r = 
 0.355, P < 0.001) and in the subgroups, namely in patients with and without HCC: r = 0.281, P < 
0.001 
 and r = 0.255, P = 0.006, respectively. The statistical correlation was maintained when considering  
each etiologic group, with higher r in Non-Viral CLD (r = 0.491, P < 0.001) and CHB (r = 0.432, P 
<  
0.001) as compared to CHC (r = 0.254, P = 0.001). In the sub-analysis where the correlation 
between the two biomarkers was analysed in each etiology group according to presence or absence 
of HCC, AFP and PIVKA-II were significantly correlated in HCC patients with viral infection (r = 
0.416, P = 0.005 in CHB and r = 0.218, P = 0.019 in CHC), but not in cirrhotics without HCC (r = 
with CHC and Non-Viral CLD (r = 0.463, P < 0.001 and r = 0.359, P = 0.047, respectively), but not 
in 
 CHB patients (r = 0.175, P = 0.354). On the contrary, in cirrhotics without HCC, the correlation 
was found in CHB patients only (r = 0.601, P = 0.002). PIVKA-II and ALT correlated significantly 
in HCC patients with Non-Viral CLD only (r = 0.595, P < 0.001); whereas no correlation was 
observed in HCC patients with viral infection (r = 0.179, P = 0.344 in CHB and r = 0.194, P = 
0.191 in CHC) or in cirrhotic patients without HCC (r = 0.156, P = 0.477 in CHB; r = 0.298, 242 P 
= 0.124 in CHC and r = 0.001), respectively. The diagnostic performances of the two biomarkers 
were evaluated using fixed cut-off values: the thresholds with the best performance were 10 ng/mL 
for AFP (Se 52.5%, Sp 75.2%, PPV 81.7%, NPV 42.9%, and DA 59.8%) and 40 mAU/mL for 
PIVKA-II (Se 78.7%, Sp 62.5%, PPV 81.9%, NPV 57.7%, DA 73.5%). When the ROC curves 
were plotted according to CLD etiology, the highest AUROCs were obtained for both PIVKA-II 
and AFP in CHB group. AFP showed a progressive loss of diagnostic performance compared to 
PIVKA-II in CHC and Non-Viral CLD patients: AUROC (95% CI) AFP/PIVKA-II = 0.822 (0.728–
0.915)/0.833 (0.739–0.926) in CHB; 0.648 (0.560–0.736)/0.732 (0.650–0.814) in CHC; 0.640 
(0.540–0.740)/0.806 (0.722–  
0.889) in Non-Viral CLD (Fig. 2). Then, we evaluated the diagnostic performances of the two 
biomarkers, alone or in combination, in each group of etiology using different cut-off values (Table 
3). In CHB and Non-Viral CLD patients AFP resulted highly specific for HCC even at low cut-off 
values (100% Specificity at the threshold of 20 ng/mL), but with poor Sensitivity 
(29.5% and 24.1%). In CHC patients 100% Specificity was achieved at 400 ng/mL cut-off with 
11.3% Sensitivity. Overall the diagnostic performance of PIVKAII was higher than that of AFP: 
PIVKA-II diagnostic accuracies ranged between 62.7 to 73.5% as compared to 40.5 to 59.8% for 
AFP. The same hold true when each etiologic group was considered. The best DA was obtained 
combining the two biomarkers and considering as positive AFP > 20 ng/mL or PIVKA-II >48 
mAU/mL: 78.2% for CHB (Se 72.7%, Sp 85.3%), 77% for Non-Viral CLD (Se 83.5%, Sp 61.8%) 
and 75% for CHC (Se 81.7%, Sp 57.8%) (Table 3). 
 
4. Discussion 
In a cohort of 388 consecutive patients with liver cirrhosis with and without HCC we studied the 
impact of the etiology of the underlying CLD as confounding factor influencing the diagnostic 
performance of AFP and PIVKA-II as HCC biomarkers. AFP and PIVKAII serum levels were 
confirmed to be higher in HCC than non-HCC patients independently of CLD etiology. Overall 
there was a significant correlation between the two biomarkers, but with low ⇢ value. In cirrhotic 
patients without HCC, AFP levels differed significantly according to etiology and were higher in 
patients with CHC and Non-Viral CLD than in CHB (CHC vs CHB, P < 0.001; CHC vs Non-Viral, 
P < 0.001; CHB vs Non-Viral, P = 0.004). Since all the patients with CHC had an active liver 
disease whereas the majority (68.7%) of CHB patients were treated with nucleos(t)ide analogue and 
had normal ALT, these results are consistent with the evidence that AFP serum levels are 
influenced significantly by hepatocyte regeneration, triggered by necro-inflammation in patients 
with active chronic liver disease [27]. In the same way AFP serum levels were higher in CHC than 
in CHB and Non-Viral CLD (P = 0.007 vs CHB and P < 0.001 vs Non-Viral CLD) in patients with 
HCC. About a half of HCC in CHB cirrhotic patients (27 out of 48, 56.3%) occurred in treated 
patients with normal ALT. At variance with AFP, PIVKA-II serum levels 
are not influenced by liver regeneration since PIVKAII is a prothrombin precursor without 
coagulation activity which increases following an impaired vitamin-K-dependent post-
transcriptional carboxylation of glutamic acid residues at the N-terminus in the HCC cells only [28]. 
Consistently we did not find any significant difference between PIVKA-II levels in patients with 
CLD of different etiology and/or correlation with ALT levels. On the other hand we found a highly 
significant correlation (P < 0.001) between PIVKA-II and HCC size in all the etiology groups in 
accordance with the specific association of this biomarker with tumour angiogenesis. PIVKA-II 
serum levels were positively correlated with tumour vascularization and PIVKA-II was shown to 
stimulate the growth and migration of endothelial cells by activating the vascular endothelial cell 
receptor-2 (VEGFR-2) acting as a paracrine pro-angiogenetic factor [13,14,29]. Interestingly 
PIVKA-II levels were significantly higher in Non-Viral HCC patients (P = 0.042 vs CHB and P = 
0.047 vs CHC) (Fig. 1). These findings could stem from a different pathogenic pathway of hepato-
carcinogenesis in this subset of CLD. Alternatively, higher PIVKA-II median levels could be 
explained by the presence of a more advanced neoplastic disease (as suggested by the 
BCLC stage at diagnosis) in Non-Viral HCC patients as compared to CHB and CHC patients who 
are usually followed-up by more stringent US surveillance. AFP levels did not correlate with 
tumour size in patients with elevated ALT, possibly because of a confounding fraction of the 
biomarker released by regenerating hepatocytes. Consistently, a correlation between AFP levels and 
HCC size was present only in absence of liver necro-inflammation, namely in treated CHB patients 
with normal ALT levels. The finding that both HCC biomarkers and age were the only variables 
independently associated with HCC at multivariate analysis further supports the potential role of 
these two biomarkers for the HCC surveillance in high risk populations. However, because of the 
widely variable diagnostic performances of AFP and PIVKA-II in different cohorts, the combined 
use of these biomarkers did not find yet a homogeneous application in international guidelines. 
Some investigators reported the superiority of AFP compared to other biomarkers [15,30] whereas a 
meta-analysis of forty-nine studies indicated PIVKAII as the best single marker for HCC even in 
presence of a significant heterogeneity of sensitivity and specificity rates [31]. Major differences of 
the study  populations in clinical (age distribution, CLD etiology, disease activity, race, tumour 
stage) and methodological determinants (type of study, assay characteristics, cut-off values, 
reference standards) are the more reasonable explanations of these discrepancies. Accordingly, two 
recent Italian studies analysed the diagnostic performance of AFP and PIVKA-II reporting different 
results: Se/Sp 81.1%/86.4% vs 55.0%/55.0% for 
AFP and 77.8%/90.9%vs 60.0%/90.0%for PIVKA-II. However, these studies used different assays 
and cutoffs (AFP 5.3 ng/ml; PIVKA-II 0.4 ng/ml and AFP 20 ng/mL; PIVKA-II 47 mAU/mL, 
respectively) and the percentage of cirrhotics in the non-HCC group was relatively low [26,32]. In 
our study we report the diagnostic performances of the two biomarkers using different cut-offs 
defined by previous studies [23–26]. Our results confirm that PIVKA-II is a better marker than AFP 
in differentiating HCC from non-HCC cirrhotic patients, although there are significant differences 
according to the etiology of the underlying CLD. Specifically, AUROC values of PIVKA-II and 
AFP are similar in CHB patients (0.833 and 0.822), but different in CHC (0.732 and 0.648) and 
Non-Viral CLD (0.806 and 0.640) (Fig. 2). These findings agree with previous observations 
suggesting a better AFP diagnostic performance in HBV-infected patients undergoing antiviral 
therapy [33] where the prolonged remission of necro inflammation reduces the confounding fraction 
of AFP generated by liver regeneration which is enhanced in active liver disease. The significant 
impact of CLD etiology on the diagnostic performance of AFP and PIVKA-II and the changing 
epidemiologic patterns of CLD in different areas of the world explain why the combined use of 
AFP and PIVKA-II has become a routine diagnostic tool since many years in some countries, such 
as Japan where HCV infection was the prevalent cause of CLD [17].  
In Italy HCV infection prevailed in HCC patients during the last decades, whereas a significant 
increase of Non-Viral CLD is reported in more recent years [3]. Our results support the utility of 
combining AFP and PIVKA-II with the highest gain in diagnostic accuracy was observed in CHC 
patients. Major limitations of our study are the retrospective design and the sample size which do 
not allow to validate new cut-off values. Nevertheless, we could confirm the relevant impact of the 
etiology of CLD and disease activity on the diagnostic performance of AFP and PIVKA-II. 
Accordingly, these co-factors should be taken into account for the definition of the clinically 
meaningful cut-offs since the use of the same threshold in each group of etiology provides widely 
different sensitivity, specificity and diagnostic accuracies rates. Another limitation of the study is 
represented by the etiology ratio that could not be precisely balanced and specifically the number of 
CHB non-HCC patients was higher (26.9%) than CHB HCC patients (18.6%). Furthermore we 
could not perform any evaluation in order to assess the cost-effectiveness of these biomarkers for 
HCC surveillance. Finally we did not completely rule out possible interferences on PIVKA-II serum 
levels  by alcohol intake and vitamin-K deficiency or Warfarin therapies. Future studies should take 
into account the variability due to the aforementioned confounding factors, together with the 
individual biological variability which is inherently associated to each biomarker. Therefore, an 
important step ahead to ameliorate the diagnostic performance of the combined used of AFP and 
PIVKA-II would be the definition of the biologically meaningful delta variation of the individual 
baseline level of the two biomarkers in consecutive serum specimens collected prospectively from 
patients at the  
same risk of developing HCC.  
In conclusion, the overall results of our study show that the diagnostic performance of AFP and 
PIVKA-II as HCC biomarkers is significantly influenced by the etiology of CLD and provide a 
consistent rationale for using the combination of AFP and PIVKA-II for HCC diagnosis in clinical 
practice, particularly in the subgroups of HCV infected and Non-Viral CLD patients. Moreover, 
these results suggest that the optimization of the two biomarkers cut-offs according to the etiology 
and activity of CLD (absence of active liver disease, sustained virologic response in both HBV, 
HCV and HDV infections) represents an important goal of future prospective studies. 
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